Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation
14 12월 2023 - 3:41AM
Business Wire
- Court ruled in favor of Acadia on all
grounds
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
the U.S. District Court for the District of Delaware has granted
summary judgment to Acadia, confirming validity of the NUPLAZID®
(pimavanserin) '740 composition of matter patent. The court ruled
in favor of Acadia on all grounds. The ruling came in Acadia’s
litigation against MSN Laboratories Pvt. Ltd., MSN Pharmaceuticals,
Inc. and other ANDA (Abbreviated New Drug Application) filers and
concludes this litigation in the District Court.
“We are very pleased that the Court has made its final decision
on this matter, ruling strongly in favor of Acadia. We advanced two
legal arguments to support our position and, while we only needed
to win on one, the Court ruled in our favor on both arguments,”
said Steve Davis, President and Chief Executive Officer of Acadia
Pharmaceuticals. “This outcome demonstrates Acadia’s commitment to
protecting our innovations in new treatments for disorders with
high unmet need.”
The ‘740 composition of matter patent protects NUPLAZID into
2030. Acadia markets two forms of NUPLAZID, a 34mg capsule and a
10mg tablet. In addition to the ‘740 patent, Acadia has an issued
method of use patent that protects the 10mg tablet to 2037 and
multiple issued formulation patents that protect the 34mg capsule
into 2038.
About NUPLAZID® (pimavanserin) Pimavanserin is a selective
serotonin inverse agonist and antagonist preferentially targeting
5-HT2A receptors. These receptors are thought to play an important
role in neuropsychiatric disorders. In vitro, pimavanserin
demonstrated no appreciable binding affinity for dopamine
(including D2), histamine, muscarinic, or adrenergic receptors.
Pimavanserin was approved for the treatment of hallucinations and
delusions associated with Parkinson’s disease psychosis by the U.S.
Food and Drug Administration in April 2016 under the trade name
NUPLAZID. In addition, Acadia is developing pimavanserin as a
potential treatment for the negative symptoms of schizophrenia.
About Acadia Pharmaceuticals Acadia is advancing breakthroughs
in neuroscience to elevate life. For 30 years we have been working
at the forefront of healthcare to bring vital solutions to people
who need them most. We developed and commercialized the first and
only approved therapies for hallucinations and delusions associated
with Parkinson’s disease psychosis and for the treatment of Rett
syndrome. Our clinical-stage development efforts are focused on
treating the negative symptoms of schizophrenia, Prader-Willi
syndrome, Alzheimer’s disease psychosis and neuropsychiatric
symptoms in central nervous system disorders. For more information,
visit us at www.acadia.com and follow us on LinkedIn and
Twitter.
Forward-Looking Statements Statements in this press release that
are not strictly historical in nature are forward-looking
statements. These statements include but are not limited to
statements regarding the timing of future events. These statements
are only predictions based on current information and expectations
and involve a number of risks and uncertainties. Actual events or
results may differ materially from those projected in any of such
statements due to various factors, including the risks and
uncertainties inherent in drug development, approval and
commercialization. For a discussion of these and other factors,
please refer to Acadia’s annual report on Form 10-K for the year
ended December 31, 2022, as well as Acadia’s subsequent filings
with the Securities and Exchange Commission. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. All forward-looking statements are qualified in their
entirety by this cautionary statement and Acadia undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231213328305/en/
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818)
395-3043 media@acadia-pharm.com
Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858)
261-2872 ir@acadia-pharm.com
Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950
ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024